Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction.
about
A Peptide to Reduce Pulmonary Edema in a Rat Model of Lung TransplantationTreating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.Extracellular Hb enhances cardiac toxicity in endotoxemic guinea pigs: protective role of haptoglobin.Sphingosine 1-phosphate in acute dengue infectionBiomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness.THE ENDOTHELIUM IN SEPSIS.Mathematical modelling and a systems science approach to describe the role of cytokines in the evolution of severe dengueLPS causes pericyte loss and microvascular dysfunction via disruption of Sirt3/angiopoietins/Tie-2 and HIF-2α/Notch3 pathways.Could Biomarkers Direct Therapy for the Septic Patient?Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?Endothelial barrier dysfunction in septic shock.How could biomarkers of ARDS and AKI drive clinical strategies?Biomarkers of hypoxia, endothelial and circulatory dysfunction among climbers in Nepal with AMS and HAPE: a prospective case-control study.In Development-A New Paradigm for Understanding Vascular Disease.Pathogenesis of vascular leak in dengue virus infection.Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.Tissue inhibitor of metalloproteinases 3-dependent microvascular endothelial cell barrier function is disrupted under septic conditions.Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo.Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax.The endothelium, a protagonist in the pathophysiology of critical illness: focus on cellular markers.Special focus: endothelial activation/dysfunction.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
P2860
Q27346720-FC068B48-B658-4F25-8DDA-3253095FD3ACQ28076034-84DF472F-AC57-4DE7-BC01-E5FC42DF5EEFQ33584834-806FFC23-6285-4617-B10C-6D7466FBD693Q35435898-BC53B642-140D-45DC-AF26-6DE74E82D974Q35817214-CDD2114A-1996-4102-BB23-A4438CF9C0DCQ35922159-27895CB4-4F80-4868-AF6F-18338616081DQ36305184-C1B2FD74-E220-4AB8-9A75-F6CC0934D327Q36574347-333E0055-48A2-4877-A3DE-B5880EA8ADDAQ36852546-3439A10D-4545-47E6-819F-6387D964B8FFQ37466271-A7647E71-357F-4D88-A11C-696E96B4D562Q38270705-12816C0A-800D-4CAA-93F7-C8805BFFCED9Q38715149-255CC084-9821-40D1-BDB8-006C312FDF12Q38893539-7E2E7949-CB6A-43EC-95FF-DFD498A0F76CQ39193273-28B893F9-4026-4CC3-8888-C522C3053CBAQ39258872-AEB65ED7-FD21-4CFF-A022-274D1821E1C0Q40099285-5F5D3C11-B0C3-450A-BBD0-B387BB40A0ACQ40749386-6E3A6B49-4D1B-41B2-89F6-C3EDDB146719Q40996335-93E649C3-D67D-4888-B605-8B9851C48B7CQ41576520-5830348C-D123-4C6C-B631-C12F5898571FQ42146414-7E81A025-9EB1-40B2-BE50-C2764C19FF50Q42314994-F1837E14-AA24-47AD-B33F-123A2DA6E9E7Q47682409-D704FD8D-C128-484D-8ED1-9FB312FA9664
P2860
Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging therapeutic strategie ...... al activation and dysfunction.
@en
type
label
Emerging therapeutic strategie ...... al activation and dysfunction.
@en
prefLabel
Emerging therapeutic strategie ...... al activation and dysfunction.
@en
P2860
P921
P356
P1433
P1476
Emerging therapeutic strategie ...... al activation and dysfunction.
@en
P2093
Ilyse Darwish
W Conrad Liles
P2860
P304
P356
10.4161/VIRU.25740
P5008
P577
2013-07-16T00:00:00Z
2013-08-15T00:00:00Z